The U.S. District Court for the Northern District of Illinois has allowed certain claims in a class action lawsuit against Quincy Bioscience LLC, the makers of Prevagen, to proceed. The court found that the plaintiff plausibly alleged deceptive marketing practices due to questionable scientific backing for the product’s purported cognitive benefits. However, the court ruled that the plaintiff lacked standing to contest advertisements she had not directly encountered, such as television commercials and online ads she did not actually view. More details on the court’s decision can be found here.
Prevagen, marketed as a dietary supplement aimed at improving memory, has faced scrutiny about the validity of its claims. The plaintiff alleges that the product’s advertised benefits do not align with its scientific support. In previous assessments, the Federal Trade Commission and New York’s Attorney General also questioned the legitimacy of the studies touted by Quincy Bioscience. The court’s recent decision underscores the challenges companies might face when consumer protection laws intersect with advertising claims.
This ruling echoes an ongoing pattern where courts are increasingly scrutinizing the robustness of scientific claims behind health and wellness products. Legal experts often emphasize the necessity for manufacturers to present clear and factual evidence supporting their claims, especially in a landscape where consumer protection regulations are stringent. The outcome of the Prevagen case could potentially signal broader implications for how dietary supplements are marketed across the United States. Quincy Bioscience continues to defend its product, asserting that Prevagen’s efficacy is scientifically validated.